| Project/Area Number |
17591484
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
TSUJI Tsuyoshi Nara Medical University, School of Medicine, assistant professor., 医学部, 講師 (50295804)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAKI Miyako Nara Medical University, School of Medicine, chief professor, 医学部, 教授 (00033358)
YOSHIKAWA Yoshiro Nara Medical University, School of Medicine, assistant professor, 医学部, 講師 (40343420)
NAKAJIMA Chikako Nara Medical University, School of Medicine, assistant professor, 医学部, 助手 (50336848)
TAMURA Yamato Nara Medical University, School of Medicine, assistant professor, 医学部, 助手 (20382301)
桑田 俊之 奈良県立医科大学, 医学部, 助手 (00398439)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2006: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2005: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | SERCA2a / Phospholamban / RNAi / Gene transfer / failing heart |
|---|
| Research Abstract |
We have reported that the cardiac function and the survival rate are improved to the rat severe heart failing model by over expressed of the sarcoplasmic reticulum Ca^<2+>ATPase (SERCA2a) gene. Moreover, we have enhanced the SERCA2a function in controlling Phospholamban (PLB) that is the suppresser protein of SERCA2a by the anti sense method. We have paid attention to ratio of PLB and SERCA2a (PLB/SERCA2a ratio) and treated serious failing hearts. It is difficult to try gene transfer for a large animal and the human whole heart using adenovirus. The method has not been established yet. While the gene expression is discovered to be suppressed by RNAi (RNA interference : RNA interference) in C. elegans in recent topics, there is a similar mechanism in the mammal. It has been reported the very effective method of gene silencing by using small RNA in mammal. Then, the aim of this research is to develop a new safety and effective treatment for serious heart failure, combining RNAi and the gene transfer. It came to be able to gene transfer in this year under the ultrasonic guide instead of under the X-ray. Moreover, we had heard an information of invalidity of siRNA in vivo at another laboratory though it was effective in vitro. It has been difficult for us to get effective siRNA for PLB in vivo. While we have reported repeatedly about the effectiveness of SERCA2a for the serious heart failure. Now we start non-viral safety procedure, near future it will be a promising clinical application.
|
